Selection and characterization of a novel agonistic human recombinant anti-Trail-R2 minibody with anti-leukemic activity

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 73-83

  Secchiero, Paola ^a   Sblattero, D ^b   Chiaruttini, C ^c   Melloni, E ^a   Macor, P ^c   Zorzet, S ^c   Tripodo, C ^d   Tedesco, F ^c   Marzari, R ^c   Zauli, G ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apoptosis; Minibodies; TRAIL; TRAIL receptors

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENT; DEATH RECEPTOR 5; MINIBODY 2.23; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PHAGE DISPLAY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 62649096816     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200109     Document Type: Article

References (44)

1. Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptor system in hematopoiesis and endothelial cell biology Cytokine Growth Factor Rev 2006; 17:245-57.
2. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007; 26:3745-57.
3. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26:3621-30.
4. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6:564-7.
5. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Iacone A, Zauli G. TRAIL regulates normal erythroid maturation through an ERK- dependent pathway. Blood 2004; 103:517-22.
6. Di Pietro R, Secchiero P, Rana R, et al. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 2001; 97:2596-603.
7. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7:383-5.
8. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201:331-40.
9. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci 2006; 110:279-91.
10. Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8:2306-2310.
11. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 2004; 59:304-10.
12. Jung K, Lein M, Stephan C, Von Hösslin K, Semjonow A, Sinha P, Loening SA, Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111:783-91.
13. Mizutani Y, Matsubara H, Yamamoto K, et al. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 2004; 101:1794-802.
14. De Toni EN, Thieme SE, Herbst A, et al. OPG is regulated by {beta}-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 2008; 14:4713-8.
15. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954-60.
16. Pukac L, Kanakaraj P, Humphreys R, et al. HGS- ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92:1430-41.
17. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25:1390-5.
18. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13: 6187-94.
19. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non- small cell lung cancer. Lung Cancer 2008; 61:82-90.
20. Sblattero D, Bradbury A. Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol 2000; 18:75-80.
21. Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, Bradbury A, Tedesco F. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol 2002; 32: 2773-82.
22. Sblattero D, Bradbury A. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology 1998; 3:271-8.
23. Borgatti P, Mazzoni M, Carini C, et al. Changes of nuclear protein kinase C activity and isotype composition in PC12 cell proliferation and differentiation. Exp Cell Res 1996; 224:72-8.
24. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G, Capitani S, Zauli G. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood 2001; 98:2220-8.
25. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani D, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase- dependent pathway. Blood 2002; 100:2421-9.
26. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S, Albini A, Zauli G. Antiangiogenic activity of the MDM2 antagonist Nutlin-3. Circ Res 2007; 100:61-9.
27. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P. TNF-related apoptosis inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 2004; 104: 2044-50.
28. Zauli G, Rimondi E, Stea S, Baruffaldi F, Stebel M, Zerbinati C, Corallini F, Secchiero P. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27/kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 2008; 214:117-25.
29. Vitale M, Zamai L, Falcieri E, Zauli G, Gobbi P, Santi S, Cinti C, Weber G. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells. Cytometry 1997; 30: 61-6.
30. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67:10556-63.
31. Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitors Nutlins as an innovative therapeutic tool for the treatment of hematological malignancies. Curr Pharm Des 2008; 14:2100-10.
32. Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem 2005; 48: 4491-9.
33. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004; 25:158-64.
34. Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL-receptor-2, predict poor survival in diffuse large B-cell lymphoma. Blood 2007; 110:4396-4405.
35. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005; 54:11-20.
36. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor- related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299:31-8.
37. Hollinger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature Biotechnol 2005; 23:1126-36.
38. Jain M, Kamal N, Batra SK. Engineering antibodies for clinical applications. Trends Biotechnol 2007; 25:307-16.
39. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nature Rev Drug Discov 2007; 6:349-356.
40. Secchiero P, Zauli G. TNF-related apoptosis- inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008; 15:42-48.
41. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008; 263:14-25.
42. Daniel D, Yang B, Lawrence DA, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007; 110: 4037-46.
43. Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 2007; 13:4556-64.
44. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007; 9:395-403.